Our recent progress on a water-soluble curcumin monoglucronide (CMG) will be presented at the GAP (Global Academic Programs) conference of Karolinska Institute in Sweden: Kanai, M., Imaizumi, A., Kakeya, H. “Development of a water-soluble curcumin monoglucronide (CMG) as a novel anticancer prodrug targeting KRAS-NF-kappa B signaling pathway”, GAP (Global Academic Programs) conference, Stockholm, Sweden, May, 2018.
Comments